Gujarat Magazine

Amyotrophic Lateral Sclerosis (ALS) Pipeline Insight 2025

Amyotrophic Lateral Sclerosis Pipeline constitutes 75+ key companies continuously working towards developing 80+ Amyotrophic Lateral Sclerosis treatment therapies, analyzes DelveInsight.

Amyotrophic Lateral Sclerosis Overview:

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative condition that primarily targets motor neurons. The disease can arise from both genetic (familial) and non-genetic (sporadic) factors, though a single definitive cause has not been identified. ALS typically impacts both upper and lower motor neurons, beginning with limb weakness and gradually progressing to paralysis and, ultimately, death.

The underlying cause of sporadic ALS remains largely unknown, though several mechanisms have been proposed, including disrupted RNA processing, oxidative stress from SOD1 mutations, inflammation, and glutamate toxicity. Familial ALS, which is less common, is linked to inherited genetic mutations such as expansions in the C9ORF72 gene and SOD1 gene mutations, typically passed down in an autosomal dominant manner.

Breathing difficulties are a major concern in ALS due to respiratory muscle weakening. Noninvasive ventilation is commonly used to manage symptoms like shortness of breath or reduced forced vital capacity (FVC), while invasive ventilation may be required in more severe cases. Difficulty swallowing (dysphagia) is also frequent and may be managed through dietary modifications or, if necessary, feeding via a gastrostomy (G-tube) to prevent weight loss.

ALS can lead to various complications, including respiratory failure, speech and mobility issues, malnutrition, fatigue, muscle spasms, and problems with saliva and mucus control. Additionally, medications used to manage ALS symptoms may cause side effects such as gastrointestinal discomfort, liver complications, or headaches.

Request for a detailed insights report on Amyotrophic Lateral Sclerosis pipeline insights @ https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Amyotrophic Lateral Sclerosis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Amyotrophic Lateral Sclerosis Therapeutics Market.

Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report

• DelveInsight’s Amyotrophic Lateral Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Amyotrophic Lateral Sclerosis treatment.

• In November 2025, Ractigen Therapeutics announced that its siRNA therapy RAG-21, which targets ALS associated with FUS gene mutations, received Orphan Drug Designation from the FDA.

• Key Amyotrophic Lateral Sclerosis companies such as Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others are evaluating new drugs for Amyotrophic Lateral Sclerosis to improve the treatment landscape.

• Promising Amyotrophic Lateral Sclerosis pipeline therapies in various stages of development include MN-166, RNS60, VM202, QRL-201, and others.

Amyotrophic Lateral Sclerosis Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Amyotrophic Lateral Sclerosis Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Amyotrophic Lateral Sclerosis market.

Download our free sample page report on Amyotrophic Lateral Sclerosis pipeline insights @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Amyotrophic Lateral Sclerosis Emerging Drugs

• MN-166: MediciNova

• RNS60: Revalesio

• VM202: Helixmith

• QRL-201: QurAlis Corporation

Amyotrophic Lateral Sclerosis Companies

More than 75 major companies are actively involved in developing treatments for Amyotrophic Lateral Sclerosis (ALS). Among them, MediciNova has drug candidates in the most advanced stages of development, currently in Phase II/III clinical trials.

DelveInsight’s report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Amyotrophic Lateral Sclerosis Therapies and Key Companies: Amyotrophic Lateral Sclerosis Clinical Trials and advancements

Amyotrophic Lateral Sclerosis Pipeline Therapeutic Assessment

• Amyotrophic Lateral Sclerosis Assessment by Product Type

• Amyotrophic Lateral Sclerosis By Stage

• Amyotrophic Lateral Sclerosis Assessment by Route of Administration

• Amyotrophic Lateral Sclerosis Assessment by Molecule Type

Download Amyotrophic Lateral Sclerosis Sample report to know in detail about the Amyotrophic Lateral Sclerosis treatment market @ Amyotrophic Lateral Sclerosis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Amyotrophic Lateral Sclerosis Current Treatment Patterns

4. Amyotrophic Lateral Sclerosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Amyotrophic Lateral Sclerosis Late-Stage Products (Phase-III)

7. Amyotrophic Lateral Sclerosis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Amyotrophic Lateral Sclerosis Discontinued Products

13. Amyotrophic Lateral Sclerosis Product Profiles

14. Amyotrophic Lateral Sclerosis Key Companies

15. Amyotrophic Lateral Sclerosis Key Products

16. Dormant and Discontinued Products

17. Amyotrophic Lateral Sclerosis Unmet Needs

18. Amyotrophic Lateral Sclerosis Future Perspectives

19. Amyotrophic Lateral Sclerosis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Amyotrophic Lateral Sclerosis Pipeline Reports Offerings

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/